Aethlon Medical to Present at the NYC Oncology Conference

Monday, October 29, 2018 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

SAN DIEGO, Oct. 29, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), an immunotherapeutic technology company focused

on unmet needs in global health, today announced that its CEO, Jim Joyce, will present at the NYC Oncology Investor Conference on Tuesday, October 30, 2018 at 10:50 a.m.
Eastern Time
.  The event is being held at Rockefeller Center, 1270 6th Avenue, New York, New York. 

About Aethlon Medical, Inc.

Aethlon Medical is focused on addressing unmet needs in global health.  The Aethlon HemopurifierŪ is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the HemopurifierŪ depletes the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The HemopurifierŪ is also an FDA designated "Breakthrough Device" related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.  You can also connect with us on Twitter, LinkedIn and Facebook.

ABOUT THE NYC ONCOLOGY INVESTOR CONFERENCE

The NYC Oncology Investor Conference 2018 hosted by OneMed Forum, and sponsored by the National Foundation for Cancer Research, the International Cancer Impact Fund, Klosters Innovation Partners, Venable Law Firm, Torreya Partners, and Marcum is the leading conference for early-stage private and public cancer investing. For more information about the conference, please visit www.nyconcologyconference.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2018, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:Jim FrakesChief Financial OfficerAethlon Medical, Inc. 858-459-7800 extension 3300Jfrakes@aethlonmedical.com

 

Cision View original content:http://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-nyc-oncology-conference-300738772.html

SOURCE Aethlon Medical, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store